Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study

Frontiers in Immunology

Laurent Daeffler¹  Jean Rommelaere²  Assia Angelova²  Antonio Marchini³  Vitaly I. Pozdeev⁴ 

[1] CNRS, UMR7178, Strasbourg, France;Infection, Inflammation and Cancer Program, German Cancer Research Center, Heidelberg, Germany;Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Center, Heidelberg, Germany;Laboratory of Oncolytic Virus Immuno-Therapeutics, Luxembourg Institute of Health, Luxembourg, Luxembourg;Université de Strasbourg, IPHC, Strasbourg, France;

关键词: oncolytic viruses;    H-1PV;    immunotherapy;    immunogenic cell death;    combination therapy;    tumor microenvironment;   

DOI  :  10.3389/fimmu.2019.01848

来源: DOAJ

【 摘 要 】

Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a “cold” immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.

【 授权许可】

Unknown